Atomo Diagnostics Ltd (AT1)
20mins delayed
Movement
1 Year Return
Atomo Diagnostics Ltd Chart
| Share price | |
| Last | |
| Change | |
| Volume | |
| Turnover | |
| Market Cap | $127.5 million |
| Today's Movement | |
| Prev. Close | |
| Open | |
| Day Range | - |
| VWAP | |
| Historical Stats | |
| 52w Range | - |
| 4w Avg Volume | |
| 4w Avg Turnover | |
| (delayed) | |
AT1 Statistics
02 June
672 / 2,239
ASX Size Rank
1yr Return
vs Sector (1yr)
-48.69%
vs ASX 200 (1yr)
-11.55%
$127.5 million
Market Cap
Share Issue
404.77 million
All Ords (%)
N/A
Short Sold
0%
Current Fundamentals
02 June
N/A
PE Ratio
EPS ($)
-
Earnings Yield
-
NTA ($)
-
N/A
Dividend Yield
DPS ($)
-
Gross Div. Yield
-
Gross DPS ($)
-
Company Overview
Atomo Diagnostics Limited (AT1) is a medical device company and is establishing an in-house assembly and packing facility in South Africa and has a commercial office in the UK. Its Rapid Diagnostic Test devices are used both by healthcare professionals and by consumers to screen for a range of diseases and medical conditions, including HIV infection.
Upcoming Calendar
Dividend History
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| No dividends paid in the last 5 years | ||||
See Upcoming Dividends for all ASX companies.
Announcements
| Date | Heading | Pages | File Size | Time |
|---|---|---|---|---|
Broker Consensus
The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.
AT1 is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.
Directors & Management
| Name | Title | Since | Bio |
|---|---|---|---|
| Dr Paul Alexander Kasian | Non-Executive Director | - |
|
| Ms Constance (Connie) Bernadette Carnabuci | Non-Executive Director | Feb 2020 |
|
| Mr John Perry Keith | Non-Executive Chairman, Non-Executive Director | Dec 2011 |
|
| Mr John Michael Kelly | Founder, Managing Director | Apr 2010 |
|
| Dr Curt Harold LaBelle | Non-Executive Director | Oct 2016 |
|
Director Transactions
AT1 directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
There are no director transactions for code AT1 in our database.
Shareholder Distribution
Shareholder Distribution data is unavailable.
Top 20 Shareholders
| Name | Shares | Capital |
|---|---|---|
| Dalraida Holdings Pty Limited | 66,160,000 | 11.79% |
| Global Health Investment Fund I LLC | 63,851,280 | 11.38% |
| Walker Group Holdings Pty Ltd | 58,285,720 | 10.39% |
| National Nominees Limited | 32,767,943 | 5.84% |
| HSBC Custody Nominees (Australia) Limited | 23,632,532 | 4.21% |
| Blueflag Holdings Pty Ltd | 17,200,000 | 3.07% |
| HSBC Custody Nominees (Australia) Limited - A/C 2 | 13,750,000 | 2.45% |
| J P Morgan Nominees Australia Pty Limited | 13,537,714 | 2.41% |
| Citicorp Nominees Pty Limited | 12,606,065 | 2.25% |
| Grand Challenges Canada | 11,390,824 | 2.03% |
| Mainstream Fund Services Pty Ltd (Perennial Private To Public Opportunities Fund) | 10,937,500 | 1.95% |
| Liverbird Pty Ltd | 9,731,653 | 1.73% |
| Sokolov Pty Limited (ATF Sokolov Trust) | 9,415,077 | 1.68% |
| I D E Pty Ltd (ATF Ide Trust) | 9,032,248 | 1.61% |
| Mark Andrew Smith | 7,790,224 | 1.39% |
| John Michael Kelly | 7,370,248 | 1.31% |
| Leo James Lynch and Judith Anne Beswick (The Beswick Lynch Superannuation Fund) | 7,321,121 | 1.30% |
| BNP Paribas Noms Pty Ltd (DRP) | 7,170,746 | 1.28% |
| Bosana Nominees Pty Ltd | 6,881,496 | 1.23% |
| Ian Fredrick Johnson | 6,879,560 | 1.23% |
| All other shareholders | 29.47 % | |
The Top 20 Shareholders of AT1 hold 70.53% of shares on issue.
AT1 Share Price History
| Date | Close | Change | % Change | Open | High | Low | Volume | Turnover |
|---|---|---|---|---|---|---|---|---|
AT1 Historical Data
Download up to 20 years of share price history.
| Year | Closing Price (30 June) | Last Trade |
|---|
Offical data as published by ASX. See more Data Downloads.
Company Details
Principal Activity: The expansion of global sales and continued development of its rapid test device technologies.
Incorporated: --
Level 2, 701-703 Parramatta Rd
Leichhardt NSW 2040
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.